{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=baricitinib&page=2", "query": { "intervention": "baricitinib", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=baricitinib&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-27T01:01:21.050Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00902486", "title": "INCB028050 Compared to Background Therapy in Patients With Active Rheumatoid Arthritis (RA) With Inadequate Response to Disease Modifying Anti-Rheumatic Drugs", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "INCB028050", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 127, "start_date": "2009-05", "completion_date": "2010-07", "has_results": true, "last_update_posted_date": "2018-09-04", "last_synced_at": "2026-09-27T01:01:21.050Z", "location_count": 41, "location_summary": "Birmingham, Alabama • Paradise Valley, Arizona • Peoria, Arizona + 38 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Paradise Valley", "state": "Arizona" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Palm Desert", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00902486" }, { "nct_id": "NCT04901325", "title": "Baricitinib in the Treatment of Adults With Pyoderma Gangrenosum (PG)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pyoderma Gangrenosum", "Skin Diseases", "Wound Heal", "Pyoderma", "Skin Ulcer" ], "interventions": [ { "name": "Baricitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Oregon Health and Science University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 5, "start_date": "2023-10-03", "completion_date": "2025-05-07", "has_results": false, "last_update_posted_date": "2025-05-13", "last_synced_at": "2026-09-27T01:01:21.050Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT04901325" }, { "nct_id": "NCT05189106", "title": "Neurodegenerative Alzheimer's Disease and Amyotrophic Lateral Sclerosis (NADALS) Basket Trial", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Amyotrophic Lateral Sclerosis", "Alzheimer Disease", "Mild Cognitive Impairment" ], "interventions": [ { "name": "Baricitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 17, "start_date": "2022-12-05", "completion_date": "2025-06-20", "has_results": true, "last_update_posted_date": "2026-06-30", "last_synced_at": "2026-09-27T01:01:21.050Z", "location_count": 2, "location_summary": "Boston, Massachusetts • Charlestown, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Charlestown", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05189106" }, { "nct_id": "NCT01683409", "title": "A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diabetic Kidney Disease" ], "interventions": [ { "name": "Baricitinib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 130, "start_date": "2012-08", "completion_date": "2014-11", "has_results": true, "last_update_posted_date": "2019-09-30", "last_synced_at": "2026-09-27T01:01:21.050Z", "location_count": 35, "location_summary": "Lancaster, California • San Diego, California • Torrance, California + 32 more", "locations": [ { "city": "Lancaster", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Torrance", "state": "California" }, { "city": "Lakewood", "state": "Colorado" }, { "city": "Fort Lauderdale", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01683409" }, { "nct_id": "NCT03899259", "title": "A Study of Baricitinib (LY3009104) in Adults With Severe or Very Severe Alopecia Areata", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Alopecia Areata" ], "interventions": [ { "name": "Baricitinib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 606, "start_date": "2019-07-08", "completion_date": "2024-11-19", "has_results": true, "last_update_posted_date": "2026-04-07", "last_synced_at": "2026-09-27T01:01:21.050Z", "location_count": 33, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Fremont, California + 29 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Fremont", "state": "California" }, { "city": "Northridge", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03899259" }, { "nct_id": "NCT05074420", "title": "A Study of Baricitinib (LY3009104) in Children With COVID-19", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Covid19", "Corona Virus Infection" ], "interventions": [ { "name": "Baricitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "18 Years", "sex": "ALL", "summary": "1 Year to 18 Years" }, "enrollment_count": 6, "start_date": "2021-12-21", "completion_date": "2024-11-04", "has_results": true, "last_update_posted_date": "2026-08-11", "last_synced_at": "2026-09-27T01:01:21.050Z", "location_count": 3, "location_summary": "Orlando, Florida • Detroit, Michigan • Cleveland, Ohio", "locations": [ { "city": "Orlando", "state": "Florida" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT05074420" }, { "nct_id": "NCT01721057", "title": "A Study in Moderate to Severe Rheumatoid Arthritis Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Baricitinib", "type": "DRUG" }, { "name": "cDMARD", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 684, "start_date": "2012-12", "completion_date": "2014-12", "has_results": true, "last_update_posted_date": "2019-09-18", "last_synced_at": "2026-09-27T01:01:21.050Z", "location_count": 48, "location_summary": "Glendale, Arizona • Peoria, Arizona • Phoenix, Arizona + 45 more", "locations": [ { "city": "Glendale", "state": "Arizona" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Fresno", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01721057" }, { "nct_id": "NCT07209267", "title": "Baricitinib Curative Repression of HIV-1", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infection", "HIV" ], "interventions": [ { "name": "Antiretroviral Therapy (ART)", "type": "DRUG" }, { "name": "Baricitinib (LY3009104) 2 mg", "type": "DRUG" }, { "name": "Baricitinib (LY3009104) 4 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 35, "start_date": "2026-10", "completion_date": "2028-01", "has_results": false, "last_update_posted_date": "2026-08-17", "last_synced_at": "2026-09-27T01:01:21.050Z", "location_count": 2, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT07209267" }, { "nct_id": "NCT03414502", "title": "Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Methotrexate", "type": "DRUG" }, { "name": "Abatacept", "type": "DRUG" }, { "name": "Adalimumab", "type": "DRUG" }, { "name": "Azathioprine", "type": "DRUG" }, { "name": "Baricitinib", "type": "DRUG" }, { "name": "Certolizumab", "type": "DRUG" }, { "name": "Etanercept", "type": "DRUG" }, { "name": "Golimumab", "type": "DRUG" }, { "name": "Hydroxychloroquine", "type": "DRUG" }, { "name": "Infliximab", "type": "DRUG" }, { "name": "Leflunomide", "type": "DRUG" }, { "name": "Minocycline", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Sarilumab", "type": "DRUG" }, { "name": "Sulfasalazine", "type": "DRUG" }, { "name": "Tofacitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Nebraska", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "ALL", "summary": "19 Years and older" }, "enrollment_count": 400, "start_date": "2007-12-10", "completion_date": "2029-03", "has_results": false, "last_update_posted_date": "2026-06-17", "last_synced_at": "2026-09-27T01:01:21.050Z", "location_count": 1, "location_summary": "Omaha, Nebraska", "locations": [ { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT03414502" }, { "nct_id": "NCT06923072", "title": "Baricitinib in the Treatment of Kohlmeier-Degos Disease in Patients With Neurological Involvement", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Kohlmeier-Degos Disease", "Malignant Atrophic Papulosis", "Degos Disease", "Papulosis, Malignant Atrophic" ], "interventions": [ { "name": "Baricitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 12, "start_date": "2026-02-18", "completion_date": "2030-12-15", "has_results": false, "last_update_posted_date": "2026-09-18", "last_synced_at": "2026-09-27T01:01:21.050Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT06923072" } ] }